donafenib

Overview

Donafenib (sorafenib-d4) is a deuterated analog of sorafenib with multi-kinase inhibitory activity (RAF1, VEGFR2/KDR, PDGFRA). Deuterium substitution at metabolically labile positions is intended to improve pharmacokinetics and tolerability relative to sorafenib. Investigated as a frontline agent in hepatocellular carcinoma (HCC).

Evidence in the corpus

• Cited in the HCC systemic therapy landscape review among next-generation agents under investigation as alternatives or successors to sorafenib PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.